|
Key results from new tiotropium studies in COPD and asthma
MENAFN.COM Highlights from the accepted abstracts include the first Phase III exacerbation and lung function data for Boehringer Ingelheim's and Pfizer's tiotropium in asthma. These results derive from two replicate studies evaluating the efficacy of once-daily … |
View full post on asthma – Google News